5/12/2006
Daxor Announces University of Pittsburgh Medical Center of Pittsburgh, PA Acquires Blood Volume Analyzer BVA-100

New York, NY May, 12 2006 - Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the University of Pittsburgh Medical Center (UPMC) of Pittsburgh , Pennsylvania .

UPMC is the premier health system in western Pennsylvania and one of the most renowned academic medical centers in the United States . As a $5 billion organization and the region’s largest employer, UPMC has reshaped the health care and economic landscape in western Pennsylvania .

UPMC created a genuinely integrated health care delivery system and aggressively recruited superb physicians and researchers to develop internationally renowned centers in transplantation, cancer, neurosurgery, psychiatry, rehabilitation, geriatrics, and women’s health, among others. Today, with 40,000 employees, UPMC comprises 19 hospitals and a network of other care sites across a 29-county service area: doctors’ offices, cancer centers, outpatient treatment centers, specialized imaging and surgery facilities, in-home care, rehabilitation sites, behavioral health care, and nursing homes.

“It’s fitting that Daxor’s first BVA-100 in Western Pennsylvania will be installed at UPMC, recognized as one of the nation’s outstanding medical centers pioneering treatments in the management of chronic diseases like congestive heart failure, asthma, and diabetes,” noted John Reyes-Guerra , Daxor’s V.P. of Sales & Marketing. Daxor’s BVA-100 will be located within UPMC’s Nuclear Medicine Department and will be utilized to diagnose blood volume derangements in various disease states.

Recent published medical reports in cardiology journals have shown that a measured blood volume, utilizing the BVA-100, is clinically superior in the diagnosis of a patient’s volume status than existing surrogate markers, lab test and physical assessments. The diagnosis and treatment of a heart failure patient’s volume derangement is critical to their care, and recent medical reports have demonstrated that treating a patient to a normal blood volume resulted in a 100% survival rate for a specific category of heart failure patients.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with a single use diagnostic kit, and measures blood volume to within a 98% accuracy. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

 

 
 
For more infomation, please contact:
Richard Dunn
Director of Operations
212-330-8502
Diane Meegan
Investor Relations
212-330-8512